Previous 10 | Next 10 |
SEATTLE, July 15, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced...
SEATTLE, July 08, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced it ha...
SEATTLE, June 11, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that ...
Opiant Pharmaceuticals (NASDAQ: OPNT ) -32% after Teva prevails in Narcan patent dispute . More news on: Opiant Pharmaceuticals, Inc., Ascena Retail Group, Inc., Ekso Bionics Holdings, Inc., Stocks on the move, , Read more ...
SEATTLE , June 5, 2020 /PRNewswire/ -- Dr. Steven Quay , MD, PhD, author and physician-scientist, announces the availability of his 158-page book, " Your COVID-19 Survival Manual: A Physician's Guide to Keep You and Your Family Healthy During the Pandemic and Beyond, " in paperback and e...
Secoo (NASDAQ: SECO ) +85% as Qudian becomes largest shareholder. More news on: Secoo Holding Limited, Summit Wireless Technologies, Inc., RCM Technologies, Inc., Stocks on the move, , Read more ...
Atossa Therapeutics ( ATOS ) recently publicized their COVID-19 drug development program, COVID-19 HOPE. The company is using a novel combination of two FDA approved drugs, to create their AT-H201 product candidate. The company believes that AT-H201 could improve lung function and reduce the a...
SEATTLE, May 29, 2020 (GLOBE NEWSWIRE) -- Dr. Steven Quay, MD, PhD, physician-scientist and CEO of Atossa Therapeutics, Inc. announced today that he and Dr. Martin Lee, PhD, Adjunct Professor of Statistics, UCLA Fielding School of Public Health, UCLA, Los Angeles, CA have published a manusc...
SEATTLE, May 28, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that i...
Nano cap Atossa Therapeutics ( ATOS +37.1% ) jumps on more than an 8x surge in volume in reaction to data from in vitro testing of COVID-19 candidate AT-H201. More news on: Atossa Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...